2009年-_UK1A8~X

Pharma 2020: Marketing the Future – Summary

Core Content

This document outlines the transformation of the pharmaceutical industry's marketing and sales strategies in the context of a rapidly evolving healthcare landscape. It highlights the need for pharmaceutical companies to adapt to new trends, regulatory changes, and shifting patient and payer expectations by rethinking traditional approaches to product promotion and value creation.

Main Trends and Key Insights

1. Changing Healthcare Landscape

• The population is aging, and chronic diseases are becoming more prevalent, increasing the burden on healthcare systems.
• Healthcare spending as a percentage of GDP is rising globally, especially in OECD countries.
• Patients and healthcare payers are becoming more involved in the decision-making process about which medicines should be used or funded.
• The rise of e-prescribing and electronic medical records (EMRs) is enabling payers to influence prescribing decisions based on outcomes data.

2. Shift in Value Determination

• The pharmaceutical industry is no longer the sole determinant of a medicine's value.
• Pay-for-performance models are gaining traction, where reimbursement is tied to the clinical outcomes of a medicine.
• Payers and providers are increasingly using pharmacoeconomic data to evaluate the cost-effectiveness of treatments.

3. Decline in Traditional Marketing Effectiveness

• Aggressive direct-to-consumer (DTC) advertising has not delivered the expected long-term benefits.
• Detailing (sales visits to doctors) is becoming less effective, especially in developed markets, due to over-saturation and stricter regulations.
• Companies like Pfizer and others have significantly reduced their sales forces, indicating a strategic shift in marketing models.

4. Rise of Patient Empowerment

• Patients are becoming more informed and influential in healthcare decisions, aided by the growth of Health 2.0 and online health resources.
• They are helping to shape which medicines remain on the market, and their expectations are influencing the definition of "good" medicines.

5. Global Market Dynamics

• The developing world is expected to see the fastest growth in medicine demand, but these markets are highly varied in terms of healthcare systems, economic conditions, and IP protection attitudes.
• E-prescribing is becoming a standard in many countries, including the US, EU, and emerging markets like India and Turkey.

Key Recommendations for Pharma

To thrive in the evolving healthcare landscape, pharmaceutical companies should:

• Recognize the interdependence of the pharmaceutical and healthcare value chains.
• Invest in medicines that align with market demand and patient needs.
• Form alliances with healthcare providers, payers, and other stakeholders to offer supporting services.
• Develop marketing and sales plans tailored for specialist therapies.
• Create organizational cultures that support specialist healthcare packages.
• Manage multi-country launches and live licensing processes effectively.
• Adopt flexible pricing models that reflect the value delivered.
• Build marketing and sales functions that are fit for the future.

Challenges and Opportunities

• Regulatory pressures are increasing, with stricter rules on marketing practices and a focus on transparency and ethics.
• Patient and payer expectations are shifting towards value-based care, which requires pharmaceutical companies to demonstrate the real-world effectiveness and cost-effectiveness of their products.
• The decline in detailing effectiveness and the reputation damage from unethical marketing practices are pushing the industry to find alternative strategies.
• The rise of personalized medicine and genomic services presents new opportunities for value generation, though these are still in early stages.

Conclusion

The future of pharmaceutical marketing in 2020 will be defined by collaboration, value-based approaches, and innovation in delivery and pricing models. Companies that fail to adapt to these changes risk being left behind in a more complex and patient-centric healthcare environment. The document concludes that the pharmaceutical industry must move from a traditional, product-centric model to one that integrates with the broader healthcare ecosystem to deliver better outcomes and sustain its value proposition.